HK1211484A1 - Bacteriophage lysin and antibiotic combinations against gram positive bacteria - Google Patents

Bacteriophage lysin and antibiotic combinations against gram positive bacteria Download PDF

Info

Publication number
HK1211484A1
HK1211484A1 HK15112347.8A HK15112347A HK1211484A1 HK 1211484 A1 HK1211484 A1 HK 1211484A1 HK 15112347 A HK15112347 A HK 15112347A HK 1211484 A1 HK1211484 A1 HK 1211484A1
Authority
HK
Hong Kong
Prior art keywords
antibiotic
plyss2
lysin
daptomycin
combination
Prior art date
Application number
HK15112347.8A
Other languages
English (en)
Chinese (zh)
Inventor
Raymond Schuch
Robert C. Nowinski
Michael Wittekind
Han Lee
Brent SCHNEIDER
Original Assignee
Contrafect Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corporation filed Critical Contrafect Corporation
Publication of HK1211484A1 publication Critical patent/HK1211484A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15112347.8A 2012-05-09 2013-05-09 Bacteriophage lysin and antibiotic combinations against gram positive bacteria HK1211484A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644944P 2012-05-09 2012-05-09
US61/644944 2012-05-09
US201261737239P 2012-12-14 2012-12-14
US61/737239 2012-12-14
PCT/US2013/040329 WO2013170015A1 (en) 2012-05-09 2013-05-09 Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Publications (1)

Publication Number Publication Date
HK1211484A1 true HK1211484A1 (en) 2016-05-27

Family

ID=49551273

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112347.8A HK1211484A1 (en) 2012-05-09 2013-05-09 Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Country Status (16)

Country Link
US (5) US10813983B2 (cg-RX-API-DMAC7.html)
EP (2) EP2849782B1 (cg-RX-API-DMAC7.html)
JP (4) JP6608697B2 (cg-RX-API-DMAC7.html)
KR (3) KR20230113404A (cg-RX-API-DMAC7.html)
CN (1) CN104736172A (cg-RX-API-DMAC7.html)
AU (3) AU2013259512B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014027842A2 (cg-RX-API-DMAC7.html)
CA (1) CA2872902A1 (cg-RX-API-DMAC7.html)
DK (1) DK2849782T3 (cg-RX-API-DMAC7.html)
ES (1) ES2784136T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211484A1 (cg-RX-API-DMAC7.html)
IL (3) IL235527B2 (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02437A (cg-RX-API-DMAC7.html)
MX (2) MX389127B (cg-RX-API-DMAC7.html)
RU (2) RU2659208C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013170015A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104780933B (zh) 2012-05-09 2020-08-28 康特拉费克特公司 使用噬菌体溶素的生物膜预防、破坏和处理
MX389127B (es) 2012-05-09 2025-03-19 Contrafect Corp Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas.
GB2543453A (en) * 2014-06-26 2017-04-19 Univ Rockefeller Acinetobacter lysins
CN107580503B (zh) * 2015-03-12 2021-07-09 迈克瑞欧斯人体健康有限公司 用于治疗细菌感染的杀菌剂与亲溶酶体碱化剂的组合
CN108135971A (zh) * 2015-09-17 2018-06-08 抗非特公司 溶素恢复/增强在肺表面活性物质存在下由此抑制的抗生素的抗菌活性的用途
JP6875756B2 (ja) * 2016-05-12 2021-05-26 コントラフェクト コーポレイション 抗細菌ポリペプチドの最小発育阻止濃度を評価および決定するための微量液体希釈方法
US11266609B2 (en) 2017-06-19 2022-03-08 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
EP3651739A4 (en) * 2017-07-10 2021-04-07 Contrafect Corporation BLOOD COMPONENT POTENTIALIZATION OF LYTIC PROTEIN ANTIBACTERIAL ACTIVITY AND RELATED METHODS AND USES
EP3758738A4 (en) * 2018-02-26 2021-12-08 Contrafect Corporation MODIFIED PLYSS2-LYSINE AND USES THEREOF
AU2019288723A1 (en) * 2018-06-22 2021-01-21 Contrafect Corporation Lysins and derivatives thereof resensitize Staphylococcus aureus and gram-positive bacteria to antibiotics
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
US12427174B2 (en) * 2019-02-05 2025-09-30 Biomedit, Inc. Probiotic compositions comprising lactobacillus reuteri strains and methods of use
EP3941504A4 (en) * 2019-03-22 2022-12-07 Contrafect Corporation METHOD FOR TREATING INFECTIOUS ENDOCARDITIS
CA3136461A1 (en) * 2019-04-11 2020-10-15 Contrafect Corporation Method of treating and preventing bone and joint infections
WO2021127452A1 (en) * 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
US20230277632A1 (en) * 2020-05-19 2023-09-07 Contrafect Corporation MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
RU2755817C1 (ru) * 2020-07-22 2021-09-21 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Способ снижения грамположительной микрофлоры в кишечнике птицы
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115105491B (zh) * 2022-07-08 2023-12-22 东北农业大学 丝氨酸在制备抑制猪链球菌药物中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
CA2251724A1 (en) * 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
KR20020000217A (ko) 1999-02-25 2002-01-05 뉴 호라이즌스 다이아그노스틱스, 인코포레이티드 스트렙토코커스 감염의 예방 및 치료 방법
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
EP1501925A4 (en) 2002-05-17 2006-10-25 New Horizons Diagnostics Corp IDENTIFICATION OF A LYTIC ENZYME ASSOCIATED WITH A PHAGE TO DETECT AND ELIMINATE RAPIDLY AND SPECIFICALLY BACILLUS ANTHRACIS
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005089527A2 (en) 2004-03-24 2005-09-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of bacillus anthracis bacteria and spores
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1917355B1 (en) 2005-08-24 2010-12-08 The Rockefeller University Ply-gbs mutant lysins
US20090053149A1 (en) 2007-08-24 2009-02-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
US8840900B2 (en) * 2008-07-03 2014-09-23 The Rockefeller University Chimeric bacteriophage lysin with activity against Staphylococci bacteria
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
EP2539446B1 (en) 2010-01-25 2017-11-01 Alere Scarborough Inc. A25 bacteriophage lysin
US20120271770A1 (en) * 2011-04-20 2012-10-25 Visa International Service Association Managing electronic tokens in a transaction processing system
CN108578685A (zh) 2011-04-21 2018-09-28 洛克菲勒大学 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
AU2012245391A1 (en) 2011-04-21 2013-11-21 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
US9016640B2 (en) 2011-04-22 2015-04-28 Rks Design, Inc. Instrument retention assembly
WO2012146738A1 (en) 2011-04-27 2012-11-01 Lysando Holding Ag New antimicrobial agents
MX389127B (es) 2012-05-09 2025-03-19 Contrafect Corp Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas.
CN104780933B (zh) * 2012-05-09 2020-08-28 康特拉费克特公司 使用噬菌体溶素的生物膜预防、破坏和处理

Also Published As

Publication number Publication date
US20180221456A1 (en) 2018-08-09
AU2018202845B2 (en) 2020-06-18
ES2784136T3 (es) 2020-09-22
IL274832A (en) 2020-07-30
JP2022058682A (ja) 2022-04-12
KR102310387B1 (ko) 2021-10-13
US20210128696A1 (en) 2021-05-06
IL235527B2 (en) 2023-10-01
US9889181B2 (en) 2018-02-13
AU2018202845A1 (en) 2018-05-10
HK1208799A1 (en) 2016-03-18
AU2013259512B2 (en) 2018-01-25
EP2849782A4 (en) 2016-01-20
EP2849782B1 (en) 2020-03-18
US20130302306A1 (en) 2013-11-14
WO2013170015A1 (en) 2013-11-14
JP2015523964A (ja) 2015-08-20
MX2014013586A (es) 2015-06-05
EP3685851A1 (en) 2020-07-29
RU2018121290A (ru) 2019-03-06
KR20150035587A (ko) 2015-04-06
EP2849782A1 (en) 2015-03-25
RU2014149351A (ru) 2016-07-10
MX2021011843A (es) 2021-10-22
KR20210121313A (ko) 2021-10-07
DK2849782T3 (da) 2020-06-22
US20210008175A1 (en) 2021-01-14
RU2659208C2 (ru) 2018-06-28
US10813983B2 (en) 2020-10-27
JP6608697B2 (ja) 2019-11-20
KR20230113404A (ko) 2023-07-28
IL308477A (en) 2024-01-01
CN104736172A (zh) 2015-06-24
CA2872902A1 (en) 2013-11-14
AU2020233683A1 (en) 2020-10-08
IL235527B1 (en) 2023-06-01
IL235527A0 (en) 2015-01-29
JP2020054370A (ja) 2020-04-09
MX389127B (es) 2025-03-19
IN2014MN02437A (cg-RX-API-DMAC7.html) 2015-07-10
AU2013259512A1 (en) 2014-12-11
BR112014027842A2 (pt) 2017-08-08
JP2018138045A (ja) 2018-09-06
US20150290299A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
AU2018202845B2 (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria
EP2846827B1 (en) Biofilm disruption with plyss2 lysin
HK40033231A (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria
HK1208799B (en) Bacteriophage lysin and antibiotic combinations against gram positive bacteria
HK1208366B (en) Biofilm disruption with plyss2 lysin